Reviparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Reviparin
Accession Number
DB09259
Type
Small Molecule
Groups
Approved, Investigational
Description

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.[1] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.[2] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[3]

Synonyms
  • Reviparin sodium
Categories
UNII
5R0L1D739E
CAS number
9041-08-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.[3]

Structured Indications
Not Available
Pharmacodynamics

Reviparin is been shown to present significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth.[1]

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Reviparin.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Reviparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Reviparin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Reviparin.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Reviparin.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
AliskirenReviparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Reviparin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Reviparin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Reviparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Reviparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Reviparin.Approved
AltrenogestThe therapeutic efficacy of Reviparin can be decreased when used in combination with Altrenogest.Vet Approved
AmilorideReviparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Reviparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Reviparin.Approved
AncrodAncrod may increase the anticoagulant activities of Reviparin.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Reviparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Reviparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Reviparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Reviparin.Approved, Investigational
Antithrombin III humanReviparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Reviparin.Approved
ApocyninApocynin may increase the anticoagulant activities of Reviparin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Reviparin.Approved, Investigational
AprotininThe therapeutic efficacy of Reviparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Reviparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Reviparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Reviparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Reviparin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Reviparin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilReviparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Reviparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Reviparin.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Reviparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Reviparin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Reviparin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Reviparin.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Reviparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Reviparin.Investigational
BevoniumBevonium may increase the anticoagulant activities of Reviparin.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Reviparin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Reviparin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Reviparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Reviparin.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Reviparin.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Reviparin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Reviparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Reviparin.Investigational
CanagliflozinReviparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanReviparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilReviparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Reviparin.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Reviparin.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Reviparin.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Reviparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Reviparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
CertoparinReviparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Reviparin.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Reviparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Reviparin.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Reviparin.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Reviparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Reviparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Reviparin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Reviparin.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Reviparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Reviparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Reviparin.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Reviparin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Reviparin.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Reviparin.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
DarexabanReviparin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Reviparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Reviparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Reviparin.Approved, Investigational
DemegestoneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Reviparin is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Reviparin.Investigational
DesirudinReviparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Reviparin.Investigational
DesogestrelThe therapeutic efficacy of Reviparin can be decreased when used in combination with Desogestrel.Approved
DextranDextran may increase the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Reviparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Reviparin.Approved, Investigational
DienogestThe therapeutic efficacy of Reviparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Reviparin.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Reviparin.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Reviparin.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Reviparin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Reviparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Reviparin.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Reviparin.Investigational
DydrogesteroneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Reviparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Reviparin.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Reviparin.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Reviparin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Reviparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Reviparin.Approved
EplerenoneReviparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Reviparin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Reviparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Reviparin.Approved
EprosartanReviparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Reviparin.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Reviparin.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Reviparin.Approved
EstroneEstrone may decrease the anticoagulant activities of Reviparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Reviparin.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Reviparin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Reviparin.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Reviparin.Withdrawn
EthynodiolThe therapeutic efficacy of Reviparin can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Reviparin.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Reviparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Reviparin.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Reviparin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Reviparin.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Reviparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Reviparin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Reviparin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Reviparin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Reviparin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Reviparin.Investigational
FimasartanReviparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
FluindioneReviparin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Reviparin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Reviparin.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
FondaparinuxReviparin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Reviparin.Approved, Investigational
ForasartanReviparin may increase the hyperkalemic activities of Forasartan.Experimental
GabexateReviparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Reviparin.Investigational
GestodeneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Reviparin.Experimental
HeminHemin may increase the anticoagulant activities of Reviparin.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Reviparin.Experimental
HeparinHeparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Reviparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Reviparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Reviparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Reviparin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Reviparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Reviparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Reviparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Reviparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Reviparin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Reviparin.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Reviparin.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Reviparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Reviparin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Reviparin.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Reviparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Reviparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Reviparin.Withdrawn
IrbesartanReviparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Reviparin.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Reviparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Reviparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Reviparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Reviparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Reviparin.Approved
LetaxabanReviparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Reviparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Reviparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Reviparin.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Reviparin.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Reviparin.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
LosartanReviparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Reviparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Reviparin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Reviparin.Approved
Megestrol acetateThe therapeutic efficacy of Reviparin can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranReviparin may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Reviparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Reviparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Reviparin.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Reviparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Reviparin.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Reviparin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Reviparin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Reviparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Reviparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Reviparin.Approved
NadroparinNadroparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Reviparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Reviparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Reviparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Reviparin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Reviparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Reviparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Reviparin.Investigational
NomegestrolThe therapeutic efficacy of Reviparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Reviparin is combined with Obinutuzumab.Approved, Investigational
OlmesartanReviparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Reviparin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Reviparin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Reviparin is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Reviparin.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Reviparin can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Reviparin.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Reviparin.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Reviparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Reviparin.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Reviparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Reviparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Reviparin.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Reviparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Reviparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Reviparin.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Reviparin.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Reviparin.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Reviparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Reviparin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Reviparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Reviparin.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Reviparin.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Reviparin.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Reviparin.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Reviparin.Approved
ProgesteroneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Reviparin.Experimental
PromegestoneThe therapeutic efficacy of Reviparin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Reviparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Reviparin.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Reviparin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Reviparin.Experimental
Protein CReviparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanReviparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeReviparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Reviparin.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Reviparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Reviparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Reviparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Reviparin.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Reviparin.Approved
RivaroxabanReviparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Reviparin.Approved, Investigational
SacubitrilReviparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Reviparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Reviparin.Approved
SaprisartanReviparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinReviparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Reviparin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Reviparin.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Reviparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Reviparin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Reviparin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Reviparin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Reviparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Reviparin.Approved, Vet Approved
SpironolactoneReviparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Reviparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Reviparin.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Reviparin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Reviparin.Approved
SulindacSulindac may increase the anticoagulant activities of Reviparin.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Reviparin.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Reviparin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Reviparin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reviparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reviparin.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Reviparin.Investigational
TasosartanReviparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanReviparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Reviparin.Approved
TenidapTenidap may increase the anticoagulant activities of Reviparin.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Reviparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Reviparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Reviparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Reviparin.Investigational
Testosterone cypionateThe therapeutic efficacy of Reviparin can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Reviparin can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Reviparin can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Reviparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Reviparin.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Reviparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Reviparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Reviparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Reviparin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Reviparin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Reviparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Reviparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Reviparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Reviparin is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Reviparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Reviparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Reviparin.Approved, Investigational
TriamtereneReviparin may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Reviparin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Reviparin.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Reviparin.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Reviparin.Approved
TroxerutinReviparin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
ValsartanReviparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Reviparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Reviparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Reviparin.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Reviparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Reviparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Reviparin.Withdrawn
Food Interactions
Not Available

References

General References
  1. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43. [PubMed:8917255]
  2. Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41. [PubMed:10759689]
  3. FDA orphan list [Link]
External Links
KEGG Drug
D03337
PubChem Substance
347910423
Wikipedia
Reviparin_sodium
ATC Codes
B01AB08 — Reviparin
MSDS
Download (52.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNeoplasms / Venous Thromboembolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility50 mg/ml'MSDS'
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 10:53 / Updated on May 01, 2018 23:58